🏅 Did you watch the start to the Paris 2024 Olympics this weekend? It's the perfect time to celebrate the "Let’s Move" campaign launched last year by the International Olympic Committee – IOC and World Health Organization This initiative emphasizes the vital connection between physical activity and brain health, encouraging everyone to move more for better overall well-being. The IOC and WHO highlight that exercise isn't just for our bodies; it’s also a powerful boost for our mental and cognitive health. 🌟 Physical activity is a modifiable factor to reduce risk of developing dementia and mental health conditions. Learn more about the campaign here: https://hubs.li/Q02JgWbl0 #Paris2024 #LetsMove #BrainHealth #MentalHealth
Creyos (formerly Cambridge Brain Sciences)
Hospitals and Health Care
Toronto, Ontario 18,584 followers
A simple & scientifically-validated digital platform for assessing cognitive function.
About us
Creyos (formerly Cambridge Brain Sciences) is a leading web-based platform for the assessment of brain health. It allows you to obtain accurate, quantified and scientifically-validated measures of key aspects of cognition, including short-term memory, attention, reasoning, and verbal ability. Creyos offers two core products – Creyos Health and Creyos Research. Built for health care practitioners, Creyos Health is an online brain health assessment service that takes seconds to set up, is engaging and enjoyable for patients, and produces a reliable and scientifically-validated cognitive assessment report in as little as 15 minutes. It is used by leading health care clinics around the world to track brain health over time as part of cognitive treatment and wellness plans. Healthcare providers using Creyos Health also have access to digital versions of many standardized patient health questionnaires. Creyos Research is made for researchers running studies on cognition in academic and commercial settings, allowing for the collection of cognitive data at scale. It has been used by many leading institutions, including Baycrest, Pfizer and Roche. Both products allow for assessment customization and online administration, require no expert technical support to administer and enable you to store and manage cognitive data securely in the cloud. Creyos maintains a global normative database of more than 85,000 participants (built off of our larger database of 12+ million completed cognitive tasks) that enables you to derive detailed comparisons of individuals to specific populations. The Cambridge Brain Sciences (now Creyos) cognitive tasks were developed in the laboratory of Dr. Adrian Owen, Canada Excellence Research Chair in Cognitive Neuroscience and Imaging (owenlab.org), over the course of his 25-year career. Over 300 scientific studies have been run to date using our tests, yielding numerous publications in leading academic journals.
- Website
-
http://www.creyos.com
External link for Creyos (formerly Cambridge Brain Sciences)
- Industry
- Hospitals and Health Care
- Company size
- 51-200 employees
- Headquarters
- Toronto, Ontario
- Type
- Privately Held
- Founded
- 2014
- Specialties
- Cognitive Assessment, Tracking Brain Health, Cognitive Health, and Cognitive Testing
Locations
-
Primary
220 King St W
Suite 300
Toronto, Ontario M5H 1K4, CA
Employees at Creyos (formerly Cambridge Brain Sciences)
Updates
-
Promising news from #AAIC24 today! Despite this progress, the current state of dementia testing and care suggests that making blood tests widely accessible will take considerable time. Scientifically validated, sensitive, online dementia screening can help bridge the gap. Discover more about online testing options and how they can identify individuals who need further evaluation, including blood testing, in our recent article: https://lnkd.in/gY9Tk8YS #dementiacare #brainhealth #cognitiveassessment
“These are absolutely transformational times.” New research reported today at the Alzheimer’s Association International Conference suggests that, in the future, highly accurate blood tests could improve diagnosis in primary care, making testing more accessible and less invasive. They could also provide a quicker path to research participation and treatment. https://cnn.it/4di02w5
-
-
We’re excited to have team members from Creyos attending #AAIC24 this week - connecting with, and learning from, other experts working to improve dementia detection, diagnosis, and care. Can’t wait to see what insights they bring back! #dementia #alzheimers #brainhealth
-
-
The Creyos team is heading to Las Vegas at the end of this week to attend the Nevada Academy of Family Physicians Summer Meeting! The event attracts healthcare leadership and family physicians across the state to discuss hot topics in primary care - spanning from preventive care and ADHD to AI and machine learning in medicine. A huge thank you to Neil Gokal MD, FAAFP for his integral contributions to making the meeting a success! 🌟 Faraz Shafaghi our Chief Product Officer, Erin Smith our Chief Marketing Officer, are excited to connect with providers on the increasing need for cognitive testing on the primary care level. Computerized cognitive testing can empower PCPs to screen for and help diagnose commonly seen conditions - dementia, ADHD, and concussion - to get more answers earlier in a patient's health journey. See you in Vegas! 🎲 #HealthcareInnovation #CognitiveTesting #DementiaCare #ADHD
-
🌍 Celebrate World Brain Day! 🧠 The World Federation Of Neurology annually celebrates World Brain Day today to promote awareness of neurological conditions and prevention strategies. Let's focus on: - Promoting early detection and prevention of neurological conditions - Ensuring equitable access to cognitive testing and treatments - Harnessing the power of health technology for better brain health outcomes Read this article from The Lancet to learn more about how we can work towards a healthier brain for everyone💪: https://hubs.li/Q02Ht-dV0 #WorldBrainHealthDay #BrainHealth #HealthEquity
World Brain Day 2024: a focus on brain health and prevention
thelancet.com
-
Gordon Stribling recently sat down with our Chief Scientific Officer, neuroscientist Adrian Owen OBE PhD for an interview with Health Tech World. They discuss how Creyos is using data, machine learning, and advanced neuroimaging techniques to help healthcare providers assess patient brain health with greater precision, efficiency, and ease. Read more about how these technological advancements are positioned to transform how ADHD and Alzheimer's are diagnosed. #healthtech #brainhealth #cognitivehealth #alzheimers #ADHD
We speak to renowned neuroscientist Adrian Owen OBE PhD about how Creyos (formerly Cambridge Brain Sciences) is making it faster, easier and cheaper to diagnose #ADHD and #Alzheimers – freeing up clinicians and giving patients peace of mind: https://lnkd.in/e2UdRKFh #healthtech
The tech accelerating ADHD and Alzheimer’s diagnosis
https://www.htworld.co.uk
-
Less than 20% of providers are integrating measurement-based care in their practice. Yet for an aging patient population, measurement-based care is critical. Why? 🔍 Challenges in Self-Reporting: Self-reports are often inconsistent and fail to provide sufficient evidence for creating robust, tailored care plans. 📊 Data-Driven Care: Objective data leads to more precise and effective treatment plans, improving patient outcomes. A major factor is the lack of effective cognitive assessment tools. The MoCA, MMSE, and Mini-Cog are limited in their abilities to detect early stages of decline—when detection is most crucial. More sensitive testing tools equip healthcare providers to detect cognitive decline earlier and monitor changes in brain health longitudinally. Read more on MBC in dementia care: https://hubs.li/Q02H074q0 #MeasurementBasedCare #DementiaCare #CognitiveTesting #DigitalHealth
What is Measurement-Based Care? Applications in Cognitive Health
creyos.com
-
McKinsey & Company predicts that by 2025, 25% of care services will shift to home-based health care, representing up to $265 billion in services within the Medicare fee-for-service and Medicare Advantage population. Key factors driving this transformation include: 🏠 Cost Efficiency: Home-based care reduces healthcare costs while maintaining or improving the quality of care. ✅ Patient Preferences: Patients increasingly prefer home-based care due to convenience, comfort, and safety, especially post-COVID-19. 💡 Innovation: Advances in technology, such as quality remote assessment tools, are crucial in enabling this transition. As this shift happens in real time, we can leverage these technological advances to decentralize services, offering quality testing and care to a wider population at a reduced cost. Read the full article here: https://hubs.li/Q02GKTcn0 #HealthcareInnovation #DigitalHealth #Telehealth #FutureOfHealthcare
From facility to home: How healthcare could shift by 2025
mckinsey.com
-
🌟 Creyos' Director of Science and Research, Mike Battista authored "The Role of AI in Early Detection of Dementia" featured in NR Times The article explores AI's crucial role in detecting early signs of age-related decline, opening incredible potential for advancements in dementia care. 🧠 Dr. Battista played an integral role in developing Creyos' dementia screener that leverages machine learning to sensitively and accurately classify performance as potentially impaired or healthy. We look forward to his contributions to the evolution of the Creyos platform and AI in healthcare. Read the feature article here: https://hubs.li/Q02G4cbv0 #AI #dementia #healthcare #machinelearning
The role of AI in early detection of dementia
https://nrtimes.co.uk
-
🔍 What do recent headlines teach us about the challenges of telehealth and responsible prescribing? While telehealth offers great convenience and improved access to quality healthcare services, its success hinges on diligent prescribing practices of controlled substances. Evidence-based healthcare approaches, such as cognitive testing, offers providers objective measures to help establish medical necessity and contribute to safe and effective treatment, especially in a telehealth setting. The importance of responsible prescribing in telehealth is underscored by the recent Done Global Inc. case. Anne Milgram of the Drug Enforcement Administration highlights that patient safety was compromised through the exploitation of the telemedicine system. Read the statement here: https://hubs.li/Q02G3YXs0 #telehealth #cognitivetesting #ADHD
Statement from DEA Administrator Anne Milgram on Done Global Inc.
dea.gov